00:00
WILEX AG, Guiding targeted therapies through diagnostics
00:10
sales, Deals, Alliances, Oncology-focused biopharmaceutical, clinical and commercial milestones, combination of therapeutics and diagnostics, Products Technologies
, At a glance
00:50
portfolio, partners, REDECTANE®, RENCAREX®, MESUPRON®, WX-554, WX-037, Antibodies, ADC Platform
, Broad portfolio and strong partners
02:25
commercialisation strategy, Therapeutics, Diagnostics, Research, Royalties, Licensing, Revenues, Licensing, income, Positioning in three segments
03:10
personalised cancer treatment, CA IX, therapeutics, diagnostics, Oncogene Science
, WILEX Group's combined offering
04:23
Carbonic Anhydrase IX (CAIX), HIF-1, biomarker, hypoxia, What is Carbonic Anhydrase IX (CAIX) and what does it do?
05:05
Diagnostic imaging
, Diagnostic imaging
05:15
REDECTANE®, renal cell cancer (ccRCC), , REDECTANE (R): Diagnosis of clear cell renal cell cancer (ccRCC)
06:18
Girentuximab (cG250), Nijmegen, MSKCC/LICR, SPA approved by FDA
, Development of the REDECTANE (R) concept
07:25
metastases, metastasis, REDECTANE (R) detects primary tumour and distant metastases
08:20
REDECTANE(R) detects also small tumours:T1a (1.7cm) ccRCC , REDECTANE(R) detects also small tumours: T1a (1.7cm) ccRCC
08:54
Final study results, REDECTANE (R): Final study results
09:27
In-vitro diagnostic
, In-vitro diagnostic
09:35
Univariate analysis of biomarker in trastuzumab-treated MBC,
Univariate Analysis, HER2, TIMP-1, uPA, Endoglin, CAIX, VEGF, Serum Biomarker, (PFS) p-value, (OS) p-value
, Univariate analysis of biomarker in trastuzumab-treated MBC
10:35
pretreatment serum CAIX, Probability, Serum CAIX , Elevated pretreatment serum CAIX predicts reduced survival
10:59
Multivariate analysis, biomarker in trastuzumab-treated MBC,
Progression-Free Survival (PFS), Conclusions
, Multivariate analysis of biomarker in trastuzumab-treated MBC
11:40
oncological biomarker, personalised medicine, kidney, cervix, lung, bladder, colon and head & neck , CAIX: important oncological biomarker in the development of personalised medicine
12:20
Forward looking statements
, Forward Looking Statements